In the race to be the first corona vaccine to hit the market, three vaccines are in the last straight line in Europe: Pfizer-BioNTech, Moderna and AstraZeneca-Oxford.
They have gone through all the necessary steps. Now they have yet to get approval from the authorities. In the meantime, they have already started production.
Based on the interim results of the phase 3 studies – which are large-scale tests on thousands of subjects – the European Medicines Agency is looking at whether they can be approved for use.
An overview of the number of doses ordered per vaccine, the options, the number of doses per person needed, the effectiveness and the status of the study they are in: